Ledraxen

Enoxaparin Sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile injectable solution for subcutaneous, intravenous, or haemodialysis use. It is indicated for patients at risk of clot formation following surgery or during dialysis.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide through regulated supply chains.

Ledraxen (enoxaparin sodium) is used in the management of venous thromboembolism and related conditions.

- Deep vein thrombosis (DVT): prevention of clot formation in at‑risk patients and treatment of established thrombosis. - Pulmonary embolism (PE): prevention of embolic events and treatment of confirmed emboli. - Haemodialysis anticoagulation: maintains circuit patency by preventing clot formation during dialysis sessions.

The most frequently reported reactions to enoxaparin sodium involve bleeding and injection‑site symptoms, while rare events can be severe.

Common Side Effects: - Bruising or hematoma at injection site: localized bleeding under the skin. - Minor bleeding: such as gum bleeding, epistaxis, or easy bruising. - Nausea: mild gastrointestinal discomfort. - Headache: transient mild headache.

Serious or Rare Side Effects: - Major hemorrhage: life‑threatening internal or external bleeding. - Thrombocytopenia (including heparin‑induced thrombocytopenia): sudden drop in platelet count. - Allergic reactions: rash, urticaria, or anaphylaxis. - Spinal or epidural hematoma: bleeding in the spinal canal after neuraxial procedures.

When using Ledraxen, clinicians should consider several safety factors to minimize bleeding risk and ensure appropriate use.

- Renal impairment: adjust dose or monitor anti‑Xa levels in patients with reduced kidney function. - Concomitant anticoagulants or antiplatelet agents: increased risk of bleeding; use with caution. - Recent or planned surgery: assess bleeding risk and possibly discontinue before procedures. - Pregnancy and lactation: safety data are limited; weigh benefits against potential risks. - Elderly patients: monitor closely for bleeding due to age‑related pharmacodynamic changes. - Store at controlled room temperature: keep in original packaging, protect from moisture and light.

Enoxaparin sodium may interact with other medicines that affect hemostasis or renal clearance.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, direct thrombin inhibitors): additive anticoagulant effect. - Antiplatelet drugs (aspirin, clopidogrel, ticagrelor): heightened bleeding risk. - Fibrinolytic agents (alteplase, streptokinase): synergistic increase in hemorrhage. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): impair platelet function and raise bleeding potential. - Neuraxial anesthesia or spinal puncture: risk of spinal/epidural hematoma.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., quinolones, macrolides): may alter platelet activity. - ACE inhibitors or diuretics: potential impact on renal function affecting drug clearance. - Statins (especially high‑dose): rare reports of increased bleeding; monitor labs.